Literature DB >> 21402850

Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.

Jason A Roberts1, Fabio Silvio Taccone, Andrew A Udy, Jean-Louis Vincent, Frédérique Jacobs, Jeffrey Lipman.   

Abstract

Despite the development of novel antibiotics active against Gram-positive bacteria, vancomycin generally remains the first treatment, although rapidly achieving concentrations associated with maximal efficacy provides an unresolved challenge. The objective of this study was to conduct a population pharmacokinetic analysis of vancomycin in a large population of critically ill patients. This was a retrospective data collection of 206 adult septic critically ill patients who were administered vancomycin as a loading dose followed by continuous infusion. The concentration-versus-time data for vancomycin in serum was analyzed by a nonlinear mixed-effects modeling approach using NONMEM. Monte Carlo simulations were performed using the final covariate model. We found that the best population pharmacokinetic model consisted of a one-compartment linear model with combined proportional and additive residual unknown variability. The volume of distribution of vancomycin (1.5 liters/kg) was described by total body weight and clearance (4.6 liters/h) by 24-hour urinary creatinine clearance (CrCl), normalized to body surface area. Simulation data showed that a 35-mg/kg loading dose was necessary to rapidly achieve vancomycin concentrations of 20 mg/liter. Daily vancomycin requirements were dependent on CrCl, such that a patient with a CrCl of 100 ml/min/1.73 m² would require at least 35 mg/kg per day by continuous infusion to maintain target concentrations. In conclusion, we have found that higher-than-recommended loading and daily doses of vancomycin seem to be necessary to rapidly achieve therapeutic serum concentrations in these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402850      PMCID: PMC3101407          DOI: 10.1128/AAC.01708-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

Authors:  J Parke; N H Holford; B G Charles
Journal:  Comput Methods Programs Biomed       Date:  1999-04       Impact factor: 5.428

Review 2.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Authors:  George L Drusano
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

Review 3.  The pharmacokinetic and pharmacodynamic properties of vancomycin.

Authors:  Michael J Rybak
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

4.  Vancomycin dosing in morbidly obese patients.

Authors:  L A Bauer; D J Black; J S Lill
Journal:  Eur J Clin Pharmacol       Date:  1998-10       Impact factor: 2.953

5.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

6.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

8.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine.

Authors:  J L Vincent; A de Mendonça; F Cantraine; R Moreno; J Takala; P M Suter; C L Sprung; F Colardyn; S Blecher
Journal:  Crit Care Med       Date:  1998-11       Impact factor: 7.598

9.  Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units.

Authors:  Simon Finfer; Rinaldo Bellomo; Jeffrey Lipman; Craig French; Geoffrey Dobb; John Myburgh
Journal:  Intensive Care Med       Date:  2004-02-12       Impact factor: 17.440

10.  Aminoglycoside volume of distribution and illness severity in critically ill septic patients.

Authors:  P E Marik
Journal:  Anaesth Intensive Care       Date:  1993-04       Impact factor: 1.669

View more
  56 in total

Review 1.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

2.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 3.  Understanding PK/PD.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2015-09-03       Impact factor: 17.440

Review 4.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

Review 5.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

6.  Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric).

Authors:  Cédric Bretonnière; Marc Leone; Christophe Milési; Bernard Allaouchiche; Laurence Armand-Lefevre; Olivier Baldesi; Lila Bouadma; Dominique Decré; Samy Figueiredo; Rémy Gauzit; Benoît Guery; Nicolas Joram; Boris Jung; Sigismond Lasocki; Alain Lepape; Fabrice Lesage; Olivier Pajot; François Philippart; Bertrand Souweine; Pierre Tattevin; Jean-François Timsit; Renaud Vialet; Jean Ralph Zahar; Benoît Misset; Jean-Pierre Bedos
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

Review 7.  Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.

Authors:  Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

8.  Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study.

Authors:  Ahmed A Mahmoud; Sean N Avedissian; Abbas Al-Qamari; Tiffany Bohling; Michelle Pham; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2020-12       Impact factor: 6.447

9.  Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Authors:  Ren Zhang; Ming Chen; Tao-Tao Liu; Jie-Jiu Lu; Chun-le Lv
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

10.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients.

Authors:  Tingjie Guo; Reinier M van Hest; Luca F Roggeveen; Lucas M Fleuren; Patrick J Thoral; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Paul W G Elbers
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.